Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | HTR2B | P41595 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | BRD1 | O95696 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047120 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2HTR7 | |
| SCHEMBL906031 | 0.95 | HTR2C (0.41) | HTR2CHTR2AHTR2BKCNH2HTR1A | |
| SCHEMBL5585330 | 0.94 | HTR2C (0.41) | HTR2CHTR2AHTR2BKCNH2HTR1A | |
| SCHEMBL906098 | 0.94 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2HTR7 | |
| SCHEMBL905942 | 0.91 | HTR2C (0.39) | HTR2CHTR2AHTR2BKCNH2HTR1A | |
| SCHEMBL906032 | 0.90 | HTR2C (0.39) | HTR2CHTR2AHTR2BKCNH2HTR1A | |
| SCHEMBL5585666 | 0.90 | HTR2C (0.40) | HTR2CHTR2AHTR2BKCNH2HTR1A | |
| SCHEMBL237951 | 0.89 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2HTR1A | |
| SCHEMBL2639684 | 0.89 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2HTR1A | |
| SCHEMBL905805 | 0.89 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | claimed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | claimed |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-8835439-B2 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases | PROXIMAGEN LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | BIOVITRUM AB (PUBL) (SE) | 2013-06-20 | — | — | US | disclosed |
| US-8410113-B2 | (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof | BIOVITRUM AB (PUBL) (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-12 | — | — | US | disclosed |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-05 | — | — | US | disclosed |
| US-8030316-B2 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine | BIOVITRUM AB (PUBL) (SE) | 2011-10-04 | — | — | US | disclosed |
| US-7820677-B2 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820677-B2 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2010-10-26 | — | — | US | disclosed |
| EP-1529043-B1 | Process for the preparation of 2-methyl piperazine derivatives. | BIOVITRUM AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142578-A1 | Novel process | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-06-29 | — | — | US | disclosed |
| EP-1645558-A1 | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | BIOVITRUM AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1529043-A1 | NOVEL PROCESS | Biovitrum AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040038981-A1 | Novel Process | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-26 | — | — | US | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000829-A1 | NOVEL PROCESS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | SUCNR1, HTR5A, HTR2C | HTR2C 3/4885HTR2A 6/4885HTR2B 20/4885 |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 10/4885 |
| US-20040038981-A1 | Novel Process | HTR1A, TPH1, HTR1B | HTR2C 6/4885HTR2A 16/4885HTR2B 14/4885 |
| US-20060142578-A1 | Novel process | HTR1A, TPH1, HTR5A | HTR2C 6/4885HTR2A 14/4885HTR2B 8/4885 |
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | HTR2C 7/4885HTR2A 14/4885HTR2B 13/4885 |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 10/4885 |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.